Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 3Lung Neoplasms 3Adenocarcinoma of Lung 3cMET-dysregulated Advanced Solid Tumors 2Melanoma 2Glioblastoma 2cMET Dysegulation Advanced Solid Tumors 1Sarcoma 1Malignant Non-small Cell Neoplasm of Lung Stage IV 1Liver Neoplasms 1Kidney Neoplasms 1Hepatic Impairment 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Bronchial Neoplasms 1Advanced Solid Tumor 1

Interventions

aldesleukin 26Sunitinib 25Interferon-alpha 21Everolimus 18Sorafenib 16Cyclophosphamide 16Filgrastim 13Bevacizumab 13Nivolumab 11Gemcitabine 11Interleukin-2 10Axitinib 10fludarabine phosphate 9Gene Expression Profiling 9temsirolimus 8Peripheral Blood Stem Cell Transplantation 8Doxorubicin 8pembrolizumab 7Radiotherapy 6Radiosurgery 6Polymerase Chain Reaction 6Ipilimumab 6Carboplatin 6sargramostim 5Ifosfamide 5Fluorouracil 5Erlotinib Hydrochloride 5Capecitabine 5Bortezomib 5atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Kidney Neoplasms × capmatinib × Clear all
NCT02019693 2023-03-21

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
20 enrolled 14 charts
Genitourinary

Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡